VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Zentalis Pharmaceuticals
ZNTL
$126M
| $125K | 0.07% |
4,415
-650
| -13% | -$18.3K |
|
|
AMAM
327
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $123K | 0.07% |
+7,468
| New | +$123K |
|
328
Phathom Pharmaceuticals
PHAT
$875M
| $122K | 0.07% |
+8,515
| New | +$122K |
|
|
VERV
329
DELISTED
Verve Therapeutics
VERV
| $119K | 0.07% |
6,359
+1,888
| +42% | +$35.4K |
|
330
AnaptysBio
ANAB
$613M
| $119K | 0.07% |
5,859
+2,411
| +70% | +$49K |
|
331
Mineralys Therapeutics
MLYS
$2.7B
| $116K | 0.07% |
+6,817
| New | +$116K |
|
332
Revolution Medicines
RVMD
$7.57B
| $115K | 0.07% |
4,306
+137
| +3% | +$3.67K |
|
|
CMPS
333
Compass Pathways
CMPS
$493M
| $114K | 0.07% |
13,799
+3,756
| +37% | +$31.1K |
|
334
Relay Therapeutics
RLAY
$710M
| $114K | 0.07% |
9,092
+3,306
| +57% | +$41.5K |
|
335
PMV Pharmaceuticals
PMVP
$77.4M
| $114K | 0.07% |
18,184
+7,762
| +74% | +$48.6K |
|
336
Keros Therapeutics
KROS
$633M
| $113K | 0.07% |
2,818
+801
| +40% | +$32.2K |
|
337
Geron
GERN
$893M
| $113K | 0.07% |
35,190
-7,861
| -18% | -$25.2K |
|
338
Arcturus Therapeutics
ARCT
$485M
| $113K | 0.07% |
3,936
-1,431
| -27% | -$41K |
|
339
Zymeworks
ZYME
$1.14B
| $113K | 0.07% |
13,054
-2,705
| -17% | -$23.4K |
|
340
Arcus Biosciences
RCUS
$1.3B
| $113K | 0.07% |
5,548
+2,538
| +84% | +$51.5K |
|
|
EQRX
341
DELISTED
EQRx, Inc. Common Stock
EQRX
| $112K | 0.07% |
60,076
+18,613
| +45% | +$34.6K |
|
342
CureVac
CVAC
$1.21B
| $111K | 0.07% |
10,692
-3,422
| -24% | -$35.7K |
|
343
Dynavax Technologies
DVAX
$1.18B
| $111K | 0.07% |
8,616
-140
| -2% | -$1.81K |
|
344
Erasca
ERAS
$457M
| $111K | 0.07% |
40,125
+19,223
| +92% | +$53.1K |
|
345
Regenxbio
RGNX
$490M
| $110K | 0.07% |
5,523
+1,266
| +30% | +$25.3K |
|
346
Arrowhead Research
ARWR
$4.02B
| $110K | 0.07% |
3,077
-1
| -0% | -$36 |
|
347
Liquidia Corp
LQDA
$2.48B
| $108K | 0.06% |
+13,817
| New | +$108K |
|
348
Allogene Therapeutics
ALLO
$255M
| $108K | 0.06% |
21,813
+8,742
| +67% | +$43.4K |
|
349
Merus
MRUS
$5.1B
| $108K | 0.06% |
4,103
-3,202
| -44% | -$84.3K |
|
350
Replimune Group
REPL
$494M
| $108K | 0.06% |
4,631
+1,008
| +28% | +$23.4K |
|